Last reviewed · How we verify

NCT06659679

Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims

Completed Last updated 25 May 2025
What this trial tests

trial testing New use of oral semaglutide in Diabetes Mellitus, Type 2 in 26,126 participants. Completed in 6 March 2025.

Timeline
24 October 2024
Primary endpoint
6 March 2025
6 March 2025

Quick facts

Lead sponsorBrigham and Women's Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment26,126
Start date24 October 2024
Primary completion6 March 2025
Estimated completion6 March 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Brigham and Women's Hospital

Who can join

50 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06659679.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing